Crohn's Disease, Inflammatory Bowel Disease, Telemedicine, Ulcerative Colitis
Conditions
Brief summary
M-TECCU is a study: multicenter, randomized and open. It consists of two parallel groups to compare the efficacy of the TECCU web-based telemonitoring system to achieve and maintain activity remission in patients with moderate-high complexity inflammatory bowel disease compared to usual clinical practice.
Detailed description
Clinical trial with an open, randomized and controlled non-inferiority medical device, in which the impact of a follow-up method through a web telemonitoring platform on the time in clinical remission of patients with complex IBD is evaluated, in comparison with the usual follow-up in outpatient clinics. Patients with complex IBD are considered to be those who receive treatment with immunosuppressants or biological therapies to control the luminal activity of their disease. Patients carry out periodic controls for the disease according to a pre-established schedule based on national and international clinical guidelines. The patients in the telemonitoring group (G\_TECCU) follow these controls through the TECCU platform, a web system that allows them to fill in questionnaires related to the clinical variables under study and communicate freely with healthcare personnel during pre-established controls and when the patient deems it necessary. On the other hand, the patients of the control group (G\_Control) carry out the controls according to the same schedule as G\_TECCU, but following the usual clinical practice.
Interventions
OTHERTECCU Software
patient monitoring by software application
Sponsors
Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Intervention model description
To compare the time in remission of patients with complex IBD (require immunosuppressants and/or biologics to control their luminal inflammatory activity) controlled with the TECCU intervention (G\_TECCU) with respect to usual clinical practice (G\_Control) after 52 weeks of follow-up.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients ≥18a * IBD (CD or UC) diagnosed according to ECCO criteria * Start treatment with immunosuppressants and/or biological therapies due to luminal activity * signed informed consent
Exclusion criteria
* Pregnant women * Presence of active perianal disease, ileoanal reservoir, or definitive stoma * Patients with mental illness or other poorly controlled illness * Patients with active cancer diagnosis * Terminal patients and/or palliative care (SECPAL) * Family members of the research team * Patients without a telephone line to connect with a mobile, tablet and/or computer / Inability to drive * Cognitive or linguistic difficulties * Patients included in another experimental study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| clinical remission | 52 weeks | To compare the time in remission of patients with complex IBD (require immunosuppressants and/or biologics to control their luminal inflammatory activity) controlled with the TECCU intervention (G\_TECCU) with respect to usual clinical practice (G\_Control) after 52 weeks of follow-up. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| cost-effectiveness | 52 weeks | Carry out a cost-effectiveness analysis based on the direct and indirect costs generated during the 12-month follow-up in G\_TECCU and G\_control. |
Countries
Spain
Contacts
PRINCIPAL_INVESTIGATORMariam Aguas
Spanish Working Group on Crohn's disease and ulcerative colitis (GETECCU)
Outcome results
None listed